MiNK Therapeutics, Inc. (INKT)
(Delayed Data from NSDQ)
$14.72 USD
-0.44 (-2.90%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $14.93 +0.21 (1.43%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
MiNK Therapeutics, Inc.'s return on equity, or ROE, is -665.42% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.12%. While this shows that INKT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
INKT 14.72 -0.44(-2.90%)
Will INKT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INKT based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for INKT
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report | INKT ...
12 Health Care Stocks Moving In Tuesday's Intraday Session
INKT: Analyst Downgrades MiNK Therapeutics to Neutral | INKT Stock News
MiNK Therapeutics (INKT) Downgraded to Neutral Amidst Valuation Concerns | INKT Stock News
MiNK Therapeutics (INKT) Downgraded by Analyst with Price Target Set | INKT Stock News